Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$39.25 USD
-1.50 (-3.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $39.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
Apellis Pharmaceuticals, Inc. [APLS]
Reports for Purchase
Showing records 221 - 240 ( 285 total )
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Glass Half Full: Our Top Biotech & Healthcare Ideas for 2021
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ALXN Takeout Demonstrates Interest, Increasing Price Target
Provider: Roth Capital Partners, Inc.
Analyst: PIERCE E
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PEGASUS Keeps Flying Out To Week 48 - Progress Towards PDUFA Continues
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Conclusive (and Inclusive) Quarterly Update For 3Q20
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Making It A Priority - Pegcetacoplan Nabs Priority Review
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
With SOBI Deal In Hand, Looking Ahead to 2021 Regulatory Decision
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Apellis Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department